Key result
Initiating low-dose aspirin before 12 weeks linked to ~71% lower preeclampsia risk vs 12-20 weeks.
Why the study?
Most clinical guidelines recommend low-dose aspirin initiation at 12 weeks of gestation because evidence supporting earlier use to reduce preeclampsia risk remains limited.
Does early initiation of low-dose aspirin before 12 weeks reduce adverse pregnancy outcomes in women with moderate-risk factors for preeclampsia?
Cohort (n=2,275)
No
Does early initiation of low-dose aspirin before 12 weeks reduce adverse pregnancy outcomes in women with moderate-risk factors for preeclampsia?
Initiating low-dose aspirin before 12 weeks of gestation in women with moderate risk factors significantly reduces the risk of preeclampsia and other adverse pregnancy outcomes compared to standard initiation at 12-20 weeks.
Answers are grounded in this paper and cite their sources.
Supports earlier aspirin in moderate-risk preeclampsia; hypothesis-generating and requires RCTs before practice change.
BACKGROUND: Preeclampsia is thought to originate from abnormal placentation during early pregnancy. Low-dose aspirin (LDA) reduces the risk of preeclampsia, but most clinical guidelines recommend initiation at 12 weeks of gestation because evidence supporting earlier use remains limited. OBJECTIVE: To evaluate whether initiation of LDA before 12 weeks of gestation improves maternal and neonatal outcomes compared with initiation between 12 and 20 weeks among women with multiple moderate-risk factors for preeclampsia. STUDY DESIGN: This retrospective cohort study included singleton pregnancies delivered at ≥20 weeks between 2015 and 2025 at a single academic center. Eligible women had at least two moderate-risk factors for preeclampsia and received daily LDA during pregnancy. Women with high-risk conditions for preeclampsia were excluded. Women were categorized according to aspirin initiation timing: early initiation before 12 weeks (n=1802) and late initiation between 12 and 20 weeks (n=473). Multivariable logistic regression analyses adjusted for maternal age, body mass index, parity, and method of conception. RESULTS: Early aspirin initiation was associated with significantly lower risks of gestational hypertension (110/1802 [6.1%] vs 118/473 [24.9%]; adjusted odds ratio [aOR] 0.24, 95% confidence interval [CI] 0.18-0.33), preeclampsia (75/1802 [4.2%] vs 74/473 [15.6%]; aOR 0.29, 95% CI 0.20-0.42), and gestational diabetes (273/1802 [15.1%] vs 136/473 [28.8%]; aOR 0.49, 95% CI 0.38-0.63). Early initiation was also associated with lower risks of preterm birth before 32 weeks (5/1802 [0.3%] vs 33/473 [7.0%]; aOR 0.04, 95% CI 0.01-0.10). Neonatal outcomes were improved, including lower risks of low Apgar score at 5 minutes (15/1802 [0.8%] vs 19/473 [4.0%]; aOR 0.26, 95% CI 0.13-0.56) and neonatal intensive care unit admission (338/1797 [18.8%] vs 147/462 [31.8%]; aOR 0.52, 95% CI 0.41-0.67). CONCLUSION: Initiation of LDA before 12 weeks of gestation was associated with reduced risks of hypertensive disorders of pregnancy, preterm birth, and neonatal morbidity compared with initiation between 12 and 20 weeks.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) conducted a cohort in Moderate-risk factors for preeclampsia (n=2,275). Early initiation of low-dose aspirin before 12 weeks vs. Late initiation between 12 and 20 weeks was evaluated on Preeclampsia (aOR 0.29, 95% CI 0.20-0.42). Early initiation of low-dose aspirin before 12 weeks was associated with a lower risk of preeclampsia compared to initiation between 12 and 20 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: